The EPS miss vs consensus is modest but may weigh on the stock near-term. However, FY27 guidance of 9-11% EPS growth and 6-7% organic revenue growth, plus the $1B buyback, provide a supportive floor. Watch the earnings call for commentary on tariff impacts and Healthcare segment margin trajectory.
Price Chart
Executive Summary
STERIS reported fiscal Q4 2026 adjusted EPS of $2.83, slightly above the $2.74 prior year but below the $2.85 consensus estimate. Revenue grew 7% to $1.6B, in line with the $1.6B consensus. The company guided fiscal 2027 adjusted EPS of $11.10-$11.30 (9-11% growth) and constant currency organic revenue growth of 6-7%, while announcing a new $1B share buyback program. The EPS miss relative to consensus and tariff/inflation headwinds are offset by solid revenue growth and positive guidance.
Key Financial Metrics
Key Facts
- Fiscal Q4 2026 adjusted EPS $2.83 vs consensus $2.85 (miss) and prior year $2.74
- Fiscal Q4 2026 revenue $1.6B, +7% YoY, in line with consensus
- Full year fiscal 2026 adjusted EPS $10.17, +10.3% YoY
- Full year fiscal 2026 revenue $5.9B, +9% YoY; constant currency organic growth 7%
- Fiscal 2027 guidance: adjusted EPS $11.10-$11.30 (9-11% growth), constant currency organic revenue growth 6-7%
- New $1B share repurchase program authorized
- Free cash flow fiscal 2026 $982.9M, up from $787.2M prior year
- Tariffs and inflation partially offset volume/price gains in Healthcare segment
Financial Impact
Q4 adjusted EPS $2.83 vs $2.85 consensus (-0.7% miss); revenue $1.6B in line; FY27 guidance implies ~$6.3B revenue and ~$11.20 EPS midpoint
Risk Factors
- Tariffs and inflation continue to pressure Healthcare segment margins
- Constant currency organic growth of 6-7% in FY27 is below FY26's 7%, potential deceleration
- Capital equipment revenue in AST declined 62% YoY in Q4, signaling lumpy demand
- Effective tax rate assumption of ~25% for FY27 could be a headwind if actual rate is higher
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292377 |
Track record
21 reports on STE
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +17.96% at T+20 after the Oct 13, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $261.91 −0.91% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $261.91 +3.34% settles Nov 19
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $261.91 +2.20% settles Nov 18
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $254.12 to $253.44 Now $261.91 +3.07% ▼ −0.27% −3.56% vs SPY
- Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $261.91 +12.82% ▲ +9.47% +14.19% vs SPY
- Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $261.91 +18.25% ▲ +3.17% +3.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers